PATENT CLAIM ANALYSIS

Application Number: 16032715
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "212060"]

Abstract:
Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Claim (Index 36):
The compound of claim  1  wherein R 1  is selected from the group consisting of: H, I, Br, \u2014NH 2 , \u2014NHCH 2 CH 3 , \u2014NHCH(CH 3 )C(F) 3 , \u2014NHC(O)OCH 3 , \u2014NHC(O)CH 3 , \u2014OCH 3 , \u2014OCH 2 CH 2 OCH 3 , \u2014OCH 2 CH 2 OH, \u2014(CH 2 ) 3 \u2014O\u2014CH 3 , CH 3 CH 2 CH 2 \u2014, cyclopropyl, CH 3 CH\u2550CH\u2014, (f1), (f2), (f3), (f4), (f5), (f6), (f7), (f8), (f9), (f10), (f11), (f12), (f13), (f14), (f15), (f16), (f17), (f18), (f19), (f20), (f21), (f22), (f23), (f24), (f25), (f26), (f27), (f28), (f29), and (f30).

Metadata:
- Claim Count in Document: 14.0
- Percentile: 95.0
- Lexical Diversity: 1.36
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15656176', '14787280', '14353381', '14431485', '15103893']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8513373218814514
- 35 USC 102 Novelty (BERT): 0.6056275677478641
- Combined Prediction Score: 0.8267663464680927
- Mean Citation Score: 463.273524
- Max Citation Score: 537.2629
- Similarity Product: 505.02888600410216

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test